AMYT
Income statement / Annual
Last year (2021), Amryt Pharma plc's total revenue was $222.54 M,
an increase of 21.87% from the previous year.
In 2021, Amryt Pharma plc's net income was -$18.17 M.
See Amryt Pharma plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
03/31/2015 |
03/31/2014 |
03/31/2013 |
03/31/2012 |
| Operating Revenue |
$222.54 M
|
$182.61 M
|
$58.12 M
|
$16.53 M
|
$15.33 M
|
$1.42 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$106.12 M |
$119.03 M |
$42.00 M |
$6.06 M |
$6.45 M |
$616,297.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$116.42 M |
$63.58 M |
$16.12 M |
$10.47 M |
$8.88 M |
$804,551.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.52 |
0.35 |
0.28 |
0.63 |
0.58 |
0.57 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$37.73 M
|
$27.62 M
|
$15.83 M
|
$10.35 M
|
$12.67 M
|
$2.47 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$8.34 M
|
$4.73 M
|
$841,000.00
|
$17.57 M
|
$13.25 M
|
$4.25 M
|
$3.33 M
|
$2.93 M
|
$1.87 M
|
$275,371.00
|
| Selling & Marketing
Expenses |
$92.00 M
|
$76.67 M
|
$35.50 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$100.34 M
|
$81.40 M
|
$36.34 M
|
$17.57 M
|
$13.25 M
|
$4.25 M
|
$3.33 M
|
$2.93 M
|
$1.87 M
|
$275,371.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$138.07 M |
$109.02 M |
$52.17 M |
$27.92 M |
$25.93 M |
$6.95 M |
$3.34 M |
$2.93 M |
$1.86 M |
$275,371.00 |
| Cost And Expenses |
$244.18 M |
$228.05 M |
$94.17 M |
$33.98 M |
$32.37 M |
$7.57 M |
$3.34 M |
$2.93 M |
$1.86 M |
$275,371.00 |
| Interest Income |
$5,000.00 |
$87,000.00 |
$92,000.00 |
$5,719.51 |
$5,998.51 |
$1,051.70 |
$185,000.00 |
$201,000.00 |
$319,071.00 |
$0.00 |
| Interest Expense |
$27.91 M |
$19.57 M |
$8.48 M |
$1.78 M |
$989,754.00 |
$127,255.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$50.74 M
|
$44.47 M
|
$12.63 M
|
$354,609.00
|
$310,722.00
|
$204,030.00
|
$6,000.00
|
$6,000.00
|
$4,558.16
|
$0.00
|
| EBITDA |
$29.10 M
|
-$977,000.00
|
-$23.42 M
|
-$17.09 M
|
-$16.73 M
|
-$5.94 M
|
$33.26 M
|
-$3.10 M
|
-$1.27 M
|
-$275,371.83
|
| EBITDA Ratio |
0.13 |
-0.01 |
-0.4 |
-1.03 |
-1.09 |
-4.18 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-0.1
|
-0.25
|
-0.62
|
-1.06
|
-1.11
|
-5.69
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$8.17 M
|
-$60.42 M
|
-$30.72 M
|
-$12.00 M
|
-$14.31 M
|
-$127,255.90
|
$189,000.00
|
-$36.81 M
|
$376,000.00
|
-$1.84 M
|
| Income Before Tax |
-$29.81 M |
-$105.86 M |
-$66.76 M |
-$29.45 M |
-$31.36 M |
-$8.21 M |
-$39.74 M |
-$2.56 M |
-$2.12 M |
-$275,371.83 |
| Income Before Tax Ratio
|
-0.13
|
-0.58
|
-1.15
|
-1.78
|
-2.05
|
-5.78
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$11.64 M |
-$1.33 M |
-$1.23 M |
$41,180.00 |
$14.31 M |
$1.93 M |
$73.18 M |
-$175,000.00 |
$2.23 M |
$550,743.00 |
| Net Income |
-$18.17 M |
-$104.53 M |
-$65.54 M |
-$29.49 M |
-$45.67 M |
-$8.21 M |
-$39.74 M |
-$2.56 M |
-$2.12 M |
-$826,115.50 |
| Net Income Ratio |
-0.08 |
-0.57 |
-1.13 |
-1.78 |
-2.98 |
-5.78 |
0 |
0 |
0 |
0 |
| EPS |
-0.39 |
-2.92 |
-4.32 |
-3.22 |
-6.14 |
-1.51 |
-3.45 |
-0.26 |
-0.33 |
-0.0816 |
| EPS Diluted |
-0.37 |
-2.92 |
-4.32 |
-3.22 |
-6.14 |
-1.51 |
-3.45 |
-0.26 |
-0.33 |
-0.0816 |
| Weighted Average Shares
Out |
$47.17 M
|
$35.76 M
|
$15.17 M
|
$9.16 M
|
$7.44 M
|
$5.44 M
|
$11.51 M
|
$9.81 M
|
$6.47 M
|
$10.12 M
|
| Weighted Average Shares
Out Diluted |
$49.40 M
|
$35.76 M
|
$15.17 M
|
$9.16 M
|
$7.44 M
|
$5.44 M
|
$11.51 M
|
$9.81 M
|
$6.47 M
|
$10.12 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
